Trial Profile
A Randomized, Double Blind Phase II Trial of Surgery, Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Temozolomide (Primary) ; Vitespen (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 21 Dec 2022 Status changed from active, no longer recruiting to completed.
- 30 Sep 2021 Status changed from recruiting to active, no longer recruiting.
- 07 May 2021 Planned number of patients changed from 108 to 310.